Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.

Literature DB >> 18299412

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.

Hiroshi Kakeya¹, Yoshitsugu Miyazaki, Hisato Senda, Tsutomu Kobayashi, Masafumi Seki, Koichi Izumikawa, Kazunori Yanagihara, Yoshihiro Yamamoto, Takayoshi Tashiro, Shigeru Kohno.

Abstract

SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18299412 PMCID： PMC2346659 DOI： 10.1128/AAC.01369-07

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates.

Authors: A S Kantarcioglu; A Yucel; V Vidotto
Journal: J Chemother Date: 2003-06 Impact factor: 1.714

2. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.

Authors: Karl V Clemons; David A Stevens
Journal: Med Mycol Date: 2006-02 Impact factor: 4.076

3. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

Authors: S Matsumoto; Y Wakai; T Nakai; K Hatano; T Ushitani; F Ikeda; S Tawara; T Goto; F Matsumoto; S Kuwahara
Journal: Antimicrob Agents Chemother Date: 2000-03 Impact factor: 5.191

4. Comparative pharmacokinetics of three preparations of the new antifungal SPK-843.

Authors: T Bruzzese; M R Galmozzi; V M Ferrari; P Sala; A Bonabello
Journal: Chemotherapy Date: 2001-12 Impact factor: 2.544

5. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors: S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal: Antimicrob Agents Chemother Date: 2000-01 Impact factor: 5.191

6. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus.

Authors: T Otsubo; S Maesaki; M A Hossain; Y Yamamoto; K Tomono; T Tashiro; J Seki; Y Tomii; S Sonoke; S Kohno
Journal: Antimicrob Agents Chemother Date: 1999-03 Impact factor: 5.191

1 in total

Review 1. Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors: Guillaume Desoubeaux; Carolyn Cray
Journal: Front Microbiol Date: 2017-05-16 Impact factor: 5.640

1 in total

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.

1. In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates.

2. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.

3. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

4. Comparative pharmacokinetics of three preparations of the new antifungal SPK-843.

5. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

6. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus.

7. Pharmacokinetics in rats of n-dimethylaminoacetyl-partricin a 2-dimethylaminoethylamide diascorbate (spk-843).

8. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.

9. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.

Review 10. Alternative modalities of administering amphotericin B: current issues.

Review 1. Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.